Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

Institutions

Publication Details

Journal
SPIRE - Sciences Po Institutional REpository
Published
2024-12-10
Primary Topic
Magnetic confinement fusion research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

SPIRE - Sciences Po Institutional REpository
Magnetic confinement fusion research
article

Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

article en

Abstract

No abstract available for this paper.
SPIRE - Sciences Po Institutional REpository
Centre Léon Bérard (FR), Centre de Recherche en Cancérologie de Lyon (FR)
Openalex Percentile: Top 41%
Magnetic confinement fusion research
OpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy · SPIRE - Sciences Po Institutional REpository (2024) | TGRS Research Map | TGRS